Answer
Based on the information in the news release, Allurion Technologies, Inc. (NYSE: ALUR) has announced that it will disclose its second‑quarter 2025 financial results on Wednesday, August 13 2025 and will hold a conference call at 8:30 a.m. ET to discuss those results and give a business update.
What the release says about future‑quarter outlook and guidance
| Item | Information in the release |
|---|---|
| Outlook for upcoming quarters | The release does not contain any statements about the company’s outlook for the remainder of 2025 (e.g., Q3, Q4) or for 2026. |
| Updated guidance (revenue, earnings, cash, etc.) | No updated guidance or revised forecasts are provided in the announcement. |
| Reference to guidance | The only forward‑looking element mentioned is that the conference call will include a “business update,” but the content of that update (including any guidance) is not disclosed in the press release. |
Implications
- No guidance is available yet. Investors and analysts will need to wait for the conference call on August 13, 2025 (or the accompanying press release/SEC filing that typically follows earnings announcements) to learn whether Allurion will issue any revised or new guidance for future quarters.
- Potential for guidance during the call. Companies often use the earnings‑release call to provide a “business update,” which can include outlook statements, revised revenue or profit targets, and operational plans. Until that call occurs (or a subsequent filing is made), we cannot confirm whether Allurion intends to issue updated guidance.
- Action for stakeholders. If you need the outlook or guidance now, the only recourse is to monitor the August 13 conference call (or the transcript/press release that follows) for any forward‑looking statements. Until then, the current public information does not contain any forward‑looking guidance.
Bottom line: The press release you provided does not contain any outlook for future quarters nor any updated guidance from Allurion. Those details, if any, are expected to be shared during the upcoming earnings call and any related post‑call materials.
Other Questions About This News
What is the market's reaction to the earnings release and conference call, and how might it affect the stock price in the short term?
Are there any risks or uncertainties highlighted in the earnings call that could impact the company's future performance?
How does Allurion's performance this quarter compare to its key competitors in the weight‑loss and metabolic health space?
What were Allurion's Q2 2025 revenue and earnings compared to the previous quarter and year?
Are there any notable changes in the company's operating expenses, margin, or cash flow?
Did the company address any regulatory or reimbursement developments that could affect its business model?
Did the company announce any new partnerships, product launches, or strategic initiatives that could impact growth?
How did the Q2 2025 results compare to analyst consensus estimates and guidance?
What is the status of the company's pipeline and any upcoming product milestones that could drive future revenue?